share_log

Oppenheimer Reiterates Outperform on Immuneering, Maintains $25 Price Target

Benzinga ·  Mar 5 07:56

Oppenheimer analyst Jay Olson reiterates Immuneering (NASDAQ:IMRX) with a Outperform and maintains $25 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment